Prognostic Markers in the Treatment of Abiraterone Acetate + Prednisolone and Enzalutamide in Castration-Resistant Metastatic Prostate Cancer
Ozgen Yildirim1, Erkan Erdur21Deparment of Medical Oncology, University of Health Sciences, Dr Abdurrahman Yurtarslan Ankara Oncology Training and Research Hospital, Ankara, Turkey, 2Department of Internal Medicine, Division of Medical Oncology, University of Health Sciences, GaziYasargil Training and Research Hospital, Diyarbakir, Turkey
Objectives: To evaluate the relationship between the neutrophil lymphocyte ratio (NLR) and progression-free survival (PFS) at the start of enzalutamide or abiraterone acetate treatment in metastatic castration-resistant prostate cancer (mCRPC) at post-docetaxel setting. Methods: Patients whom progressed after at least 6 cycles of docetaxel chemotherapy, included. Cases with <4 bone metastases, isolated lymph node metastases, or visceral metastases and uncontrolled comorbidity were excluded. Mean NLR was used for cut-off threshold. Results: 54 cases with a median age of 69 (54-75) years, with NLR below 3.34 were determined as the low NLR group, and above determined as the high NLR group. The mean PFS of the high NLR group (n=31,57.4%) was 5.3 months and low NLR group (n=23,42.6%) was 7.2 months (p<0.001). A strong negative correlation was found between NLR level and PFS (r:0.833, p<0.001). Patients with NLR regression (n=36,66.7%, regression at 6’th week of the therapy) represents 7.0 months PFS that is higher than others (5.2 months,p<0.001). Extremity bone metastases was related with low PFS (5.1 month vs 7.1, p<0.001) and high NLR (4.55 vs 2.74, p<0.001). Conclusion: NLR level above 3.34 and failure to achieve NLR regression in the first six weeks of treatment are poor prognostic factors. Keywords: Abiraterone asetate, enzalutamide, prostate cancer, neutrophil lymphocyte ratio
Cite This Article
Yildirim O, Erdur E. Prognostic Markers in the Treatment of Abiraterone Acetate + Prednisolone and Enzalutamide in Castration-Resistant Metastatic Prostate Cancer. EJMI. 2022; 6(1): 45-49
Corresponding Author: Ozgen Yildirim